Fact-checking the "AI cured cancer" hype: inside Merck/Moderna's Phase 3 mRNA vaccine win
APPSO · wechat · 2026-08-20
Viral claims of "AI cured cancer" are heavily exaggerated. The actual news: Merck and Moderna announced their personalized mRNA cancer therapy mRNA-4157 plus Keytruda met Phase 3 endpoints, significantly extending recurrence-free and distant metastasis-free survival in high-risk melanoma patients; Moderna stock surged a record 177%.
The AI role: algorithms process tumor sequencing data to predict up to 34 neoantigens most likely to trigger immune response, and Moderna's Maestro platform uses AI scheduling to keep individualized doses on time. Phase 2 already showed 44% lower recurrence risk and 65% lower distant metastasis risk versus Keytruda alone. The article also covers limits: melanoma's high mutation burden makes it an ideal target, expansion to lung, bladder and kidney cancers is still in trials, and personalization means high costs. BioNTech is developing a nearly identical therapy.
It rounds up other AI-for-science progress — AlphaFold3, Google's AI co-scientist (leukemia drug repurposing candidates in 4 hours), FutureHouse's Robin (identified a candidate for dry AMD for $10.76), Stanford's virtual lab designing 92 nanobodies — while noting most results remain preclinical.
More from AGI Musings
- The most uncomfortable AI outcome: still employed, but with no bargaining power — VraserX · 2026-08-20
- Kids born today will see us like the Middle Ages: a vision of the 2030s AI civilization — Dr_Singularity · 2026-08-20
- Shift focus from LLM hype to inference engineering, distributed systems, and hardware — max_paperclips · 2026-08-20
- AI Superforecasters Are Shifting the Value Proposition of Prediction Markets — devanshmehta · 2026-08-20
- Bezos: AI's Biggest Impact Is Empowering Every Non-Tech Company — r0ck3t23 · 2026-08-20
- Creator hit with '89% AI-written' verdict: 'Just record me typing' — TennisSkirt1628 · 2026-08-20